The European Commission has authorized Moderna’s COVID-19 vaccine as the second one available for use. The approval, which was based on the assessment of the EU’s medicines regulator, the European Medicines Agency (EMA), follows its approval of Pfizer-BioNTech’s vaccine on December 21, 2020.
This latest approval means an additional 160 million doses will be available in 2021 for EU member states under a deal between the Commission and Moderna.
Both vaccines use messenger RNA (mRNA) technology. Clinical trials found Moderna’s and Pfizer-BioNTech’s vaccines to be 94.1% and 95% effective, respectively.